Inflammatory bowel disease (IBD) is a chronic inflammatory bowel disease of unknown etiology, mainly including ulcerative colitis (UC) and crohn's disease (CD).The etiology may include environmental, infectious, immune and genetic factors.Because the etiology of inflammatory bowel disease is not clear, clinical symptoms are not specific, easy to be confused with other diseases, so the diagnosis is more difficult.Once misdiagnosis is caused by mistreatment, the result is mild but not cured, serious is life-threatening.The diagnosis of inflammatory bowel disease mainly includes the collection of clinical history, colonoscopy, imaging and mucosal histology.
This report contains market size and forecasts of Inflammatory Bowel Disease Therapy in Global, including the following market information:
Global Inflammatory Bowel Disease Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Inflammatory Bowel Disease Therapy market was valued at 17780 million in 2021 and is projected to reach US$ 22520 million by 2028, at a CAGR of 3.4% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Ulcerative Colitis Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Inflammatory Bowel Disease Therapy include Johnson & Johnson, AbbVie, Takeda Pharmaceutical Company, Abbott, Celgene Corporation, Innovate Biopharma, Cosmo Pharmaceuticals, Gilead Sciences and Pfizer. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Inflammatory Bowel Disease Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Inflammatory Bowel Disease Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Inflammatory Bowel Disease Therapy Market Segment Percentages, by Type, 2021 (%)
Ulcerative Colitis
Crohns Disease
Others
Global Inflammatory Bowel Disease Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Inflammatory Bowel Disease Therapy Market Segment Percentages, by Application, 2021 (%)
Hospital
Medical Research Organization
Other
Global Inflammatory Bowel Disease Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Inflammatory Bowel Disease Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Inflammatory Bowel Disease Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Inflammatory Bowel Disease Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Johnson & Johnson
AbbVie
Takeda Pharmaceutical Company
Abbott
Celgene Corporation
Innovate Biopharma
Cosmo Pharmaceuticals
Gilead Sciences
Pfizer